Stocktoria
Aldeyra Therapeutics, Inc. ALDX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2014-05-02
Aldeyra Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $25.7M | $48.2M | $29.5M | $47.3M | $44.9M |
| Operating income | -$35.3M | -$60.1M | -$42.8M | -$62.7M | -$56.2M |
| Interest expense | — | — | $2.1M | $1.7M | $1.7M |
| Income tax | $0 | $1,000 | $0 | $0 | $0 |
| Net income | -$33.8M | -$55.9M | -$37.5M | -$62.0M | -$57.8M |
| EPS (diluted) | $-0.56 | $-0.94 | $-0.64 | $-1.06 | $-1.07 |
| Operating cash flow | -$33.3M | -$43.2M | -$30.3M | -$56.6M | -$42.6M |
| Free cash flow | — | — | -$30.3M | -$56.7M | -$42.6M |
| Cash & equivalents | $70.0M | $54.5M | — | $144.4M | $229.8M |
| Total assets | $72.1M | $104.6M | $148.3M | $181.3M | $233.1M |
| Total liabilities | $27.8M | $33.6M | $28.5M | $30.3M | $27.4M |
| Shareholders' equity | $44.3M | $71.0M | $119.8M | $151.0M | $205.7M |
Source: SEC EDGAR filings · CIK 0001341235 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.